Here's Why You Should Hold on to Tandem Diabetes (TNDM) Stock
Zacks Investment Research | Mar 23, 2021 01:27AM ET
Tandem Diabetes Care (NASDAQ:TNDM), Inc. industry and 62.8% rise of the S&P 500 composite.
The renowned designer, developer and distributor of insulin pumps has a market capitalization of $5.64 billion. The company expects to maintain strong product performance. The company surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average surprise being 17.68%.
Let’s delve deeper.
Product Pipeline: Tandem Diabetes’ robust product pipeline lifts our sentiment. During fourth-quarter 2020, the company obtained Canadian approval for its t:slim X2 insulin pump with Control-IQ technology. Earlier to that, it launched its first-generation mobile app domestically. The company intends to launch Tandem Source in select countries outside the United States later in 2021 with a domestic launch to follow. Further, the company is currently on track to launch its app-based mobile bolus feature for the t:slim X2 in the first half of 2021.
Tandem Diabetes, based on the FDA's interoperability initiative and the timing of DexCom's clearance, is planning the commercial launch of its Control-IQ technology with the G7 sensor within a quarter following the receipt of the FDA clearance.
Strategic Deals: Tandem Diabetes’ partnership deals buoy optimism. In July 2020, the company had entered into a non-exclusive patent cross-license agreement with Medtronic (NYSE:MDT) plc To read this article on Zacks.com click here.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.